Lexeo director granted 35,000 stock options
Lexeo Therapeutics director Brenda Cooperstone received a grant of stock options covering 35,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lexeo Therapeutics director Brenda Cooperstone received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest on the earlier of one year after the grant date or the next annual meeting of stockholders, subject to her continuous service, leaving her with 35,000 derivative securities following this award.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
COOPERSTONE BRENDA
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 35,000 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
Key Figures
Option grant size: 35,000 options
Exercise price: $4.70 per share
Underlying shares: 35,000 shares
+2 more
5 metrics
Option grant size
35,000 options
Stock Option (right to buy) awarded to director
Exercise price
$4.70 per share
Conversion or exercise price of stock options
Underlying shares
35,000 shares
Common Stock underlying the options
Expiration date
June 24, 2036
Option expiration date
Holdings after grant
35,000 derivative securities
Total options held following transaction
Key Terms
Stock Option (right to buy), exercise price, expiration date, grant, award, or other acquisition, +1 more
5 terms
Stock Option (right to buy) financial
"Security title is reported as Stock Option (right to buy)."
exercise price financial
"The conversion or exercise price of the option is $4.7000."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The option has an expiration date of 2036-06-24."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"Transaction code A is described as Grant, award, or other acquisition."
continuous service financial
"Vesting is subject to the Reporting Person's continuous service on such date."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lexeo Therapeutics (LXEO) disclose about Brenda Cooperstone in this Form 4?
Lexeo Therapeutics reported that director Brenda Cooperstone received a grant of stock options for 35,000 shares of common stock. These options were awarded as compensation, not bought in the open market, and are classified as a derivative security award.
How many Lexeo Therapeutics (LXEO) options did Brenda Cooperstone receive?
Brenda Cooperstone received stock options covering 35,000 shares of Lexeo Therapeutics common stock. This entire amount represents a new derivative award, and her total derivative holdings following the transaction are also 35,000 option-linked shares.
What is the exercise price of Brenda Cooperstone’s Lexeo Therapeutics (LXEO) options?
The stock options granted to Brenda Cooperstone have an exercise price of $4.70 per share. This means she can purchase Lexeo Therapeutics common shares at $4.70 once the options vest and become exercisable, subject to the plan’s terms.
When do Brenda Cooperstone’s Lexeo Therapeutics (LXEO) options vest?
All of the options vest 100% on the earlier of one year after the grant date or the next annual meeting of stockholders. Vesting is conditioned on Brenda Cooperstone’s continuous service with Lexeo Therapeutics through the applicable vesting date.
When do Brenda Cooperstone’s Lexeo Therapeutics (LXEO) options expire?
Brenda Cooperstone’s stock options expire on June 24, 2036. After that expiration date, any unexercised options will lapse, and she will no longer be able to purchase Lexeo Therapeutics common shares under this specific award.
Was Brenda Cooperstone’s Lexeo Therapeutics (LXEO) Form 4 a market purchase or sale?
The Form 4 shows a grant or award acquisition of options, not a market trade. The transaction code is "A," indicating a compensatory grant of stock options rather than an open-market purchase or sale of Lexeo Therapeutics shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates